Please Wait.....
Report
Global Gene Therapy Market - Industry Trends and Forecast to 2030
Market Report I 2023-03-01 I 216 Pages I Data Bridge Market Research
Global gene therapy market is projected to register a CAGR of 18.3% from 2023 to 2030. The new market report contains data for the historic year 2021, the base year of calculation is 2022, and the forecast period is 2023 to 2030.
Market Segmentation:
Global Gene Therapy Market, By Vector Type (Viral Vector and Non-viral Vector), Method (Ex-vivo and In-vivo), Application (Oncological Disorders, Cardiovascular Diseases, Infectious Diseases, Rare Diseases, Neurological Disorders, and Other Diseases), End User (Cancer Institutes, Hospitals, Research institutes, and Others), Country (U.S., Canada, Mexico, Germany, France, U.K., Italy, Russia, Spain, Netherlands, Switzerland, Belgium, Turkey, Rest of Europe, China, Japan, India, Australia, South Korea, Singapore, Malaysia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific, South Africa, Rest of Middle East and Africa, Brazil, and Rest of South America) Industry Trends and Forecast to 2030
Some of the major factors contributing to the growth of the gene therapy market are:
- Rising demand of personalized medicine
- Rising prevalence of genetic disorders
- Novel approaches of gene therapy
Market Players:
The key market players for global gene therapy market are listed below:
- AGC Biologics
- Amgen, Inc.
- AnGes, Inc
- Biogen
- bluebird bio, Inc.
- Bristol Myers Squibb Company
- CHIESI Farmaceutici S.p.A.
- Dendreon Pharmaceuticals LLC
- Enzyvant Therapeutics GmbH
- Ferring B.V.
- Janssen Pharmaceuticals, Inc.
- Kite Pharma (a subsidiary of Gilead Sciences, Inc.)
- Mallinckrodt.
- Novartis AG
- Orchard Therapeutics plc.
- Oxford Biomedica
- Shanghai Sunway Biotech Co., Ltd.
- SIBONO
- Spark Therapeutics, Inc.
- uniQure NV.
TABLE OF CONTENTS
1 INTRODUCTION 21
1.1 OBJECTIVES OF THE STUDY 21
1.2 MARKET DEFINITION 21
1.3 OVERVIEW OF THE GLOBAL GENE THERAPY MARKET 21
1.4 CURRENCY AND PRICING 23
1.5 LIMITATIONS 23
1.6 MARKETS COVERED 23
2 MARKET SEGMENTATION 25
2.1 MARKETS COVERED 25
2.2 GEOGRAPHICAL SCOPE 26
2.3 YEARS CONSIDERED FOR THE STUDY 27
2.4 DBMR TRIPOD DATA VALIDATION MODEL 28
2.5 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 31
2.6 MULTIVARIATE MODELLING 32
2.7 MARKET END USER COVERAGE GRID 32
2.8 PRODUCT LIFELINE CURVE 33
2.9 DBMR MARKET POSITION GRID 34
2.10 VENDOR SHARE ANALYSIS 35
2.11 SECONDARY SOURCES 36
2.12 ASSUMPTIONS 36
3 EXECUTIVE SUMMARY 37
4 PREMIUM INSIGHTS 40
4.1 PESTEL ANALYSIS 43
4.2 PORTER FIVE ANALYSIS 44
5 UPDATE ON GERMLINE GENE THERAPY 45
5.1 GERMLINE GENE THERAPY 45
6 GLOBAL GENE THERAPY MARKET, MO 46
6.1 DRIVERS 48
6.1.1 NOVEL APPROACHES TO GENE THERAPY 48
6.1.2 INCREASING PREVALENCE OF GENETIC DISORDERS 48
6.1.3 THE GROWING INVESTMENT BY BIOTECHNOLOGY & PHARMACEUTICAL COMPANIES 49
6.1.4 GROWING DEMAND FOR PERSONALIZED MEDICINE 50
6.2 RESTRAINTS 50
6.2.1 HIGH COST OF GENE THERAPY 50
6.2.2 ETHICAL AND SAFETY CONCERNS 51
6.2.3 COMPLEXITY OF GENE THERAPY 51
6.3 OPPORTUNITIES 52
6.3.1 RISE IN STRATEGIC ACQUISITION AND PARTNERSHIP AMONG ORGANIZATIONS 52
6.3.2 RISING APPROVAL FOR GENE THERAPY PRODUCTS 52
6.4 CHALLENGES 53
6.4.1 STRINGENT REGULATIONS FOR GENE THERAPY PRODUCTS 53
6.4.2 LONG-TERM SAFETY AND EFFICACY 53
7 GLOBAL GENE THERAPY MARKET, BY VECTOR TYPE 54
7.1 OVERVIEW 55
7.2 VIRAL VECTOR 58
7.2.1 ADENOVIRUS 59
7.2.2 RETROVIRUS 59
7.2.3 LENTIVIRUS 59
7.2.4 ADENO-ASSOCIATED VIRUS 59
7.2.5 VACCINIA VIRUS 59
7.2.6 HERPES SIMPLEX VIRUS 59
7.2.7 OTHERS 59
7.3 NON-VIRAL VECTOR 59
7.3.1 LIPOFECTION 60
7.3.2 INJECTION OF NAKED DNA 60
8 GLOBAL GENE THERAPY MARKET, BY METHOD 61
8.1 OVERVIEW 62
8.2 EX-VIVO 65
8.3 IN-VIVO 65
9 GLOBAL GENE THERAPY MARKET, BY APPLICATION 67
9.1 OVERVIEW 68
9.2 ONCOLOGICAL DISORDERS 71
9.3 CARDIOVASCULAR DISEASES 71
9.4 INFECTIOUS DISEASES 72
9.5 RARE DISEASES 73
9.6 NUEROLOGICAL DISORDERS 74
9.7 OTHER DISEASES 75
10 GLOBAL GENE THERAPY MARKET, BY END USER 76
10.1 OVERVIEW 77
10.2 CANCER INSTITUTES 80
10.3 HOSPITALS 80
10.4 RESEARCH INSTITUTES 81
10.5 OTHERS 82
11 GLOBAL GENE THERAPY MARKET, BY REGION 83
11.1 OVERVIEW 84
11.2 NORTH AMERICA 89
11.2.1 U.S. 95
11.2.2 CANADA 97
11.2.3 MEXICO 99
11.3 EUROPE 101
11.3.1 GERMANY 107
11.3.2 FRANCE 109
11.3.3 U.K. 111
11.3.4 ITALY 113
11.3.5 SPAIN 115
11.3.6 RUSSIA 117
11.3.7 TURKEY 119
11.3.8 NETHERLANDS 121
11.3.9 BELGIUM 123
11.3.10 SWITZERLAND 125
11.3.11 REST OF EUROPE 127
11.4 ASIA-PACIFIC 128
11.4.1 CHINA 134
11.4.2 JAPAN 136
11.4.3 SOUTH KOREA 138
11.4.4 INDIA 140
11.4.5 AUSTRALIA 142
11.4.6 SINGAPORE 144
11.4.7 THAILAND 146
11.4.8 MALAYSIA 148
11.4.9 INDONESIA 150
11.4.10 PHILIPPINES 152
11.4.11 REST OF ASIA-PACIFIC 154
11.5 SOUTH AMERICA 155
11.5.1 BRAZIL 161
11.5.2 REST OF SOUTH AMERICA 163
11.6 MIDDLE EAST AND AFRICA 164
11.6.1 SOUTH AFRICA 170
11.6.2 REST OF MIDDLE EAST AND AFRICA 172
12 GLOBAL GENE THERAPY MARKET, COMPANY LANDSCAPE 173
12.1 COMPANY SHARE ANALYSIS: GLOBAL 173
12.2 COMPANY SHARE ANALYSIS: NORTH AMERICA 174
12.3 COMPANY SHARE ANALYSIS: EUROPE 175
12.4 COMPANY SHARE ANALYSIS: ASIA-PACIFIC 176
13 COMPANY PROFILES 177
13.1 BIOGEN 177
13.1.1 COMPANY SNAPSHOT 177
13.1.2 REVENUE ANALYSIS 177
13.1.3 COMPANY SHARE ANALYSIS 178
13.1.4 SWOT ANALYSIS 178
13.1.5 PRODUCT PORTFOLIO 179
13.1.6 RECENT DEVELOPMENT 179
13.2 KITE PHARMA 180
13.2.1 COMPANY SNAPSHOT 180
13.2.2 REVENUE ANALYSIS 180
13.2.3 COMPANY SHARE ANALYSIS 181
13.2.4 SWOT ANALYSIS 181
13.2.5 PRODUCT PORTFOLIO 182
13.2.6 RECENT DEVELOPMENT 182
13.3 NOVARTIS AG 183
13.3.1 COMPANY SNAPSHOT 183
13.3.2 REVENUE ANALYSIS 183
13.3.3 COMPANY SHARE ANALYSIS 184
13.3.4 SWOT ANALYSIS 184
13.3.5 PRODUCT PORTFOLIO 185
13.3.6 RECENT DEVELOPMENTS 185
13.4 BRISTOL-MYERS SQUIBB COMPANY. 186
13.4.1 COMPANY SNAPSHOT 186
13.4.2 REVENUE ANALYSIS 186
13.4.3 COMPANY SHARE ANALYSIS 187
13.4.4 SWOT ANALYSIS 187
13.4.5 PRODUCT PORTFOLIO 188
13.4.6 RECENT DEVELOPMENT 188
13.5 OXFORD BIOMEDICA 189
13.5.1 COMPANY SNAPSHOT 189
13.5.2 REVENUE ANALYSIS 189
13.5.3 COMPANY SHARE ANALYSIS 190
13.5.4 SWOT ANALYSIS 190
13.5.5 PRODUCT PORTFOLIO 191
13.5.6 RECENT DEVELOPMENTS 191
13.6 AGC BIOLOGICS 192
13.6.1 COMPANY SNAPSHOT 192
13.6.2 PRODUCT PORTFOLIO 192
13.6.3 RECENT DEVELOPMENT 192
13.7 ANGES, INC 193
13.7.1 COMPANY SNAPSHOT 193
13.7.2 REVENUE ANALYSIS 193
13.7.3 PRODUCT PORTFOLIO 194
13.7.4 RECENT DEVELOPMENT 194
13.8 AMGEN INC. 195
13.8.1 COMPANY SNAPSHOT 195
13.8.2 REVENUE ANALYSIS 195
13.8.3 PRODUCT PORTFOLIO 196
13.8.4 RECENT DEVELOPMENT 196
13.9 BLUEBIRD BIO, INC. 197
13.9.1 COMPANY SNAPSHOT 197
13.9.2 PRODUCT PORTFOLIO 197
13.9.3 RECENT DEVELOPMENT 197
13.10 CHIESI FARMACEUTICI S.P.A 198
13.10.1 COMPANY SNAPSHOT 198
13.10.2 REVENUE ANALYSIS 198
13.10.3 PRODUCT PORTFOLIO 199
13.10.4 RECENT DEVELOPMENT 199
13.11 DENDREON PHARMACEUTICALS LLC 200
13.11.1 COMPANY SNAPSHOT 200
13.11.2 PRODUCT PORTFOLIO 200
13.11.3 RECENT DEVELOPMENT 200
13.12 ENZYVANT THERAPEUTICS GMBH 201
13.12.1 COMPANY SNAPSHOT 201
13.12.2 RODUCT PORTFOLIO 201
13.12.3 RECENT DEVELOPMENT 201
13.13 FERRING B.V. 202
13.13.1 COMPANY SNAPSHOT 202
13.13.2 PRODUCT PORTFOLIO 202
13.13.3 RECENT DEVELOPMENT 202
13.14 JANSSEN PHARMACEUTICALS, INC. 203
13.14.1 COMPANY SNAPSHOT 203
13.14.2 PRODUCT PORTFOLIO 203
13.14.3 RECENT DEVELOPMENT 203
13.15 MALLINCKRODT. 204
13.15.1 COMPANY SNAPSHOT 204
13.15.2 REVENUE ANALYSIS 204
13.15.3 PRODUCT PORTFOLIO 205
13.15.4 RECENT DEVELOPMENT 205
13.16 ORCHARD THERAPEUTICS PLC. 206
13.16.1 COMPANY SNAPSHOT 206
13.16.2 REVENUE ANALYSIS 206
13.16.3 PRODUCT PORTFOLIO 207
13.16.4 RECENT DEVELOPMENT 207
13.17 SHANGHAI SUNWAY BIOTECH CO., LTD. 208
13.17.1 COMPANY SNAPSHOT 208
13.17.2 PRODUCT PORTFOLIO 208
13.17.3 RECENT DEVELOPMENT 208
13.18 SIBONO 209
13.18.1 COMPANY SNAPSHOT 209
13.18.2 PRODUCT PORTFOLIO 209
13.18.3 RECENT DEVELOPMENT 209
13.19 SPARK THERAPEUTICS, INC. 210
13.19.1 COMPANY SNAPSHOT 210
13.19.2 PRODUCT PORTFOLIO 210
13.19.3 RECENT DEVELOPMENT 210
13.20 UNIQURE NV. 211
13.20.1 COMPANY SNAPSHOT 211
13.20.2 REVENUE ANALYSIS 211
13.20.3 PRODUCT PORTFOLIO 212
13.20.4 RECENT DEVELOPMENT 212
14 QUESTIONNAIRE 213
15 RELATED REPORTS 216
- Not Sure / Need Reassuring
- Confirm Content
-
Content is provided by our partners and every effort is made to make Market Report details as clear as possible. If you are not sure the exact content you require is included in this study you can Contact us to double check. To do this you can:
Use the ‘? ASK A QUESTION’ below the license / prices and to the right of this box. This will come directly to our team who will work on dealing with your request as soon as possible.
Write to directly on support@scotts-international.com with details. Please include as much information as possible including the name of report or link so our staff will be able to work on you request.
Telephone us directly on 0048 603 394 346 and an experienced member of team will be on hand to answer.
-
- Sample Pages
-
With the vast majority of our partners we can obtain Sample Pages to support your decision. This is something we can arrange without revealing your personal details.
It is important to note that we will not be able to provide you the exact data or statistics such as Market Size and Forecasts. Sample pages usually confirm the layout or the Categories included in Charts and Graphs, excluding specific data.
To ask for Sample Pages by contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Check for Alternatives
-
Whilst we try to make our online platform as easy to use as possible there is always the possibility that a better alternative has not been found in your search.
To avoid this possibility Contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346 and a Senior Team Member can review your requirements and send a list of possibilities with opinions and recommendations.
-
- Confirm Content
- Prices / Formats / Delivery
- Prices
-
All prices are set by our partners and should be exactly the same as those listed on their own websites. We work on a Revenue share basis ensuring that you never pay more than what is offered elsewhere.
Should you find the price cheaper on another platform we recommend you to Contact us as we should be able to match this price. You can Contact us though through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Discounts
-
As we work in close partnership with our Partners from time to time we can secure discounts and assist with negotiations, this is part of our personalised service to you.
Discounts can sometimes be arranged for speedily placed orders; multiple report purchases or Higher License purchases.
To check if a Discount is possible please Contact our experienced team through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Available Currencies
-
Most Market Reports on our platform are listed in USD or EURO based on the wishes of our Partners. To avoid currency fluctuations and potential price differentiations we do not offer the possibility to change the currency online.
Should you wish to pay in a different currency to that advertised online we do accept payments in USD, EURO, GBP and PLN. The price will be calculated based on the relevant exchange rate taken from our National Bank.
To pay in a different above currency to that advertised online please Contact our team and a quotation will be sent within a couple of hours with payment details.
-
- Licenses
-
License options vary from Partner to Partner as is usually based on the number of Users that will benefitting from the report. It is very important that License ordered is not breached as this could have potential negative consequences for you individually or your employer.
If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.
-
- Global Site License
-
The Global Site License is the most comprehensive license available. By selecting this license, the Market Report can be shared with other ‘Allowed Users’ and any other member of staff from the same organisation regardless of geographic location.
It is important to note that this may exclude Parent Companies or Subsidiaries.
If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.
-
- Formats
-
The most common format is PDF, however in certain circumstances data may be present in Excel format or Online, especially in the case of Database or Directories. In addition, for certain higher license options a CD may also be provided.
If you have questions or need clarification about the specific formats we recommend you to Contact us and a detailed explanation will be provided.
-
- Delivery
-
Delivery is fulfilled by our partners directly. Once an order has been placed we inform the partner by sharing the delivery email details given in the order process.
Delivery is usually made within 24 hours of an order being placed, however it may take longer should your order be placed prior to the weekend or if otherwise specified on the Market Report details page. Additionally, if details have been not fully completed in the Order process a delay in delivery is possible.
If a delay in delivery is expected you will be informed about it immediately.
-
- Shipping Charges
-
As most Market Reports are delivered in PDF format we almost never have to add additional Shipping Charges. If, however you are ordering a Higher License service or a specific delivery format (e.g. CD version) charges may apply.
If you are concerned about additional Shipping Charges we recommend you to Contact us to double check.
-
- Prices
- Ordering
- By Credit Card
-
We work in Partnership with PayU to ensure payments are made securely in a fast and effortless way. PayU is the e-payments division of Naspers.
Naspers operates in over 133 International Markets and ranks 3rd Globally in terms of the number of e-commerce customers served.
For more information on PayU please visit: https://www.payu.pl/en/about-us
-
- By Money Transfer
-
If you require an invoice prior to payment, this is possible. To ensure a speedy delivery of the Market Report we require all relevant company details and you agree to maximum payment terms of 30 days from receipt of order.
With our regular clients deliver of the Market Report can be made prior to receiving payment, however in some circumstances we may ask for payment to be received before arranging for the Market Report to be delivered.
-
- By Credit Card
- Security
- Website security
-
We have specifically partnered with leading International companies to protect your privacy by using different technologies and processes to ensure security.
Everything submitted to Scotts International is encrypted via SSL (Secure Socket Layer) and all personal information provided to Scotts International is stored on computer systems with limited access in controlled environments.
-
- Credit Card Security
-
We partner with PayU (https://www.payu.pl/en/about-us) to ensure all credit card payments are made securely in a fast and effortless way.
PayU offers 250+ various payment channels and eWallet services across 4 continents allowing buyers to pay electronically, whether on a computer or a mobile device.
-
- Website security